{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:21:51Z","timestamp":1791181311429,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.4065\/80.12.1568","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T20:26:10Z","timestamp":1232742370000},"page":"1568-1574","source":"Crossref","is-referenced-by-count":188,"title":["The Role of Aspirin in the Prevention of Thrombotic Complications of Thalidomide and Anthracycline-Based Chemotherapy for Multiple Myeloma"],"prefix":"10.4065","volume":"80","author":[{"given":"Rachid","family":"Baz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandice","family":"Kottke-Marchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordan","family":"Srkalovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Yiannaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Faiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rony Abou","family":"Jawde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Zeldis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad A.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/80.12.1568_bib1","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/cncr.10946","article-title":"A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients","volume":"95","author":"Hussein","year":"2002","journal-title":"Cancer"},{"issue":"suppl","key":"10.4065\/80.12.1568_bib2","first-page":"560s","article-title":"Updated results from a randomized multicenter trial of DVd vs VAd in patients with newly diagnosed multiple myeloma [abstract]","volume":"14S","author":"Rifkin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.12.1568_bib3","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood.V104.11.2415.2415","article-title":"A phase II trial of doxil, vincristine and reduced schedule dexamethasone (DVd) for patients with relapsed or refractory multiple myeloma [abstract]","volume":"104","author":"Masci","year":"2004","journal-title":"Blood"},{"key":"10.4065\/80.12.1568_bib4","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.4065\/80.12.1568_bib5","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood"},{"key":"10.4065\/80.12.1568_bib6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2141.2003.04473.x","article-title":"Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma","volume":"122","author":"Kropff","year":"2003","journal-title":"Br J Haematol"},{"key":"10.4065\/80.12.1568_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00001721-200204000-00003","article-title":"Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications","volume":"13","author":"Zangari","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.4065\/80.12.1568_bib8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","article-title":"Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment","volume":"1","author":"Minnema","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.4065\/80.12.1568_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J Haematol"},{"key":"10.4065\/80.12.1568_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-2003-40963","article-title":"Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies","volume":"29","author":"Deitcher","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.4065\/80.12.1568_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/B:THRO.0000014589.17314.24","article-title":"Cancer and thrombosis: mechanisms and treatment","volume":"16","author":"Deitcher","year":"2003","journal-title":"J Thromb Thrombolysis"},{"key":"10.4065\/80.12.1568_bib12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.4065\/80.12.1568_bib13","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1200\/JCO.2004.05.111","article-title":"Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials","volume":"22","author":"Durie","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.4065\/80.12.1568_bib14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3949\/ccjm.69.9.721","article-title":"Advances in diagnosing and excluding pulmonary embolism: spiral CT and D-dimer measurement","volume":"69","author":"Carman","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"10.4065\/80.12.1568_bib15","first-page":"126","article-title":"Diagnosis of venous thromboembolic disease in cancer patients","volume":"17","author":"Gomes","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"10.4065\/80.12.1568_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2141.2003.04456.x","article-title":"A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience","volume":"122","author":"Jacobson","year":"2003","journal-title":"Br J Haematol"},{"key":"10.4065\/80.12.1568_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"key":"10.4065\/80.12.1568_bib18","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/blood-2002-06-1674","article-title":"Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy [letter]","volume":"100","author":"Cavo","year":"2002","journal-title":"Blood"},{"key":"10.4065\/80.12.1568_bib19","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"key":"10.4065\/80.12.1568_bib20","first-page":"209a","article-title":"Correlation of thrombotic\/embolic events (TE) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD) [abstract]","volume":"100","author":"Weber","year":"2002","journal-title":"Blood"},{"key":"10.4065\/80.12.1568_bib21","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/sj.leu.2403533","article-title":"Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy [letter]","volume":"18","author":"Minnema","year":"2004","journal-title":"Leukemia"},{"key":"10.4065\/80.12.1568_bib22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611610513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611610513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T21:18:47Z","timestamp":1589491127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611610513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0025619611610513"],"URL":"https:\/\/doi.org\/10.4065\/80.12.1568","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}